NEW YORK, Jan. 7 (GenomeWeb News) -- Myriad Genetics of Salt Lake City, Utah, and Abbott Laboratories today unveiled a new pharmacogenetics program and announced the expansion of a collaboration between the two companies.
Financial details were not provided. However, Abbott will fund all research under this collaboration and will retain sole ownership of the results. Myriad will have first rights on any personalized medicine products for reference lab uses that may result, the company said in a statement.
The companies will collaborate on research to identify genetic variation within the general population around drug targets in variuous stages of development. Myriad will provide its high-throughput sequencing technologies and mutation screening software to analyze samples from various populations to identify genetic polymorphisms.